Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Green

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Plos One|July 14, 2017
Host niche may determine disease-driven extinction riskMark Blooi, Alexandra E Laking, An Martel, et al.
Neurophotonics|June 12, 2023
Can pain under anesthesia be measured? Pain-related brain function using functional near-infrared spectroscopy during knee surgeryKeerthana Deepti Karunakaran, Ke Peng, Stephen Green, et al.
Plos Medicine|April 22, 2022
Brain-based measures of nociception during general anesthesia with remifentanil: A randomized controlled trialKeerthana Deepti Karunakaran, Barry D Kussman, Ke Peng, et al.
Neurophotonics|February 3, 2022
fNIRS brain measures of ongoing nociception during surgical incisions under anesthesiaStephen Green, Keerthana Deepti Karunakaran, Robert Labadie, et al.
Psychotherapy and Psychosomatics|January 16, 2020
The Leeds Risk Index: Field-Test of a Stratified Psychological Treatment Selection AlgorithmJaime Delgadillo, Sarah Appleby, Sarah Booth, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2015
Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffoldBernard Barlaam, Sabina Cosulich, Martina Fitzek, et al.
Molecular Cancer Therapeutics|June 11, 2009
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenograftsKate F Byth, Andrew Thomas, Gareth Hughes, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidinesGloria A Breault, Rebecca P A Ellston, Stephen Green, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2017
Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumoursBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidinesJohn F Beattie, Gloria A Breault, Rebecca P A Ellston, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Plos One|July 14, 2017
Host niche may determine disease-driven extinction riskMark Blooi, Alexandra E Laking, An Martel, et al.
Neurophotonics|June 12, 2023
Can pain under anesthesia be measured? Pain-related brain function using functional near-infrared spectroscopy during knee surgeryKeerthana Deepti Karunakaran, Ke Peng, Stephen Green, et al.
Plos Medicine|April 22, 2022
Brain-based measures of nociception during general anesthesia with remifentanil: A randomized controlled trialKeerthana Deepti Karunakaran, Barry D Kussman, Ke Peng, et al.
Neurophotonics|February 3, 2022
fNIRS brain measures of ongoing nociception during surgical incisions under anesthesiaStephen Green, Keerthana Deepti Karunakaran, Robert Labadie, et al.
Psychotherapy and Psychosomatics|January 16, 2020
The Leeds Risk Index: Field-Test of a Stratified Psychological Treatment Selection AlgorithmJaime Delgadillo, Sarah Appleby, Sarah Booth, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2015
Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffoldBernard Barlaam, Sabina Cosulich, Martina Fitzek, et al.
Molecular Cancer Therapeutics|June 11, 2009
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenograftsKate F Byth, Andrew Thomas, Gareth Hughes, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidinesGloria A Breault, Rebecca P A Ellston, Stephen Green, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2017
Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumoursBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidinesJohn F Beattie, Gloria A Breault, Rebecca P A Ellston, et al.
Pageof 6